logo
Plus   Neg
Share
Email
Comment

MMRC And Synta Pharma Begin Ganetespib Clinical Trial In Multiple Myeloma

Synta Pharmaceuticals Corp. (SNTA) and the Multiple Myeloma Research Consortium or MMRC announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals, as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADE) for the treatment of relapsed multiple myeloma.

The trial, made possible by the funding up to $1 million by the Multiple Myeloma Research Foundation (MMRF), will be conducted through the MMRC. The MMRC is a consortium of sixteen world-renowned academic institutions and community centers whose mission is to accelerate the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
J.M. Smucker Co. Tuesday announced a voluntary recall of some shipments of dog food, including Gravy Train, Kibbles 'N Bits, Ol' Roy, and Skippy canned/wet dog food, after finding "extremely low levels" of pentobarbital. Pentobarbital is a barbiturate drug that is most commonly used in animals as... Amazon.com Inc. (AMZN) Tuesday announced that its Prime members can earn 5% back on Whole Foods Market purchases when using Amazon Prime Rewards Visa Card. With this latest discount offer, Amazon Prime members who shop using the Amazon Prime Rewards Visa Card now enjoy 5 percent back on Whole Foods... Lucky Charms' new marshmallow - the magical unicorn is ready to attract kids and cereal lovers. This is the first marshmallow to be introduced in the last ten years.
comments powered by Disqus
Follow RTT